One Biosciences, a biotechnology company specializing in clinical-grade single-cell tumor transcriptomic profiling for precision oncology, has completed a €15 million Series A financing round led by Redmile Group and Blast, with support from several other investors. This funding brings their total to over €20 million, including seed financing from Home Biosciences.
Their innovative technology generates detailed tumor profiles, providing insights that can enhance clinical decision-making, improve patient selection, and optimize clinical trials.
How the funding will be used: The proceeds from the financing will accelerate the clinical development of One Biosciences’ flagship OneMap platform and support the scaling of strategic partnerships with pharmaceutical and biotech companies.
KEY QUOTES:
“This funding enables us to translate our breakthrough single-cell technology into real-time insights that could directly inform physician decision-making, improve patient care, and accelerate drug development. The extraordinary support we have received from this group of leading global investors reinforces our conviction and fast-tracks our route to market.”
Hedi Ben Brahim, CEO of One Biosciences
“This investment coupled with our established capacity to train our AI algorithms with proprietary single-cell patient datasets will further substantiate our ability to predict the response to most classes of oncology therapeutics from clinical grade specimens.”
Dr. Céline Vallot, Co-Founder of One Biosciences and group leader at Curie Institute
“Widespread use of next generation sequencing (NGS) profiling has led to substantial advances in cancer care but the clinical benefit remains limited to small patient subsets. We believe clinical grade single cell profiling has the potential to catalyze the next generation of diagnostic and therapeutic advances “.
Dr Mehdi Touat, Assistant Professor, Assistance Publique – Hôpitaux de Paris AP-HP, Pitié-Salpêtrière and Paris Brain Institute
